Eli Lilly & Co. (LLY)
1154.08
-20.53
(-1.75%)
USD |
NYSE |
Aug 31, 14:51
Eli Lilly Cash from Investing (Quarterly) : -15.40B for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.40B |
| March 31, 2026 | -3.916B |
| December 31, 2025 | -2.802B |
| September 30, 2025 | -2.983B |
| June 30, 2025 | -1.835B |
| March 31, 2025 | -3.352B |
| December 31, 2024 | -1.920B |
| September 30, 2024 | -4.005B |
| June 30, 2024 | -2.199B |
| March 31, 2024 | -1.178B |
| December 31, 2023 | -2.924B |
| September 30, 2023 | -3.080B |
| June 30, 2023 | -459.10M |
| March 31, 2023 | -688.80M |
| December 31, 2022 | -860.50M |
| September 30, 2022 | -923.40M |
| June 30, 2022 | -463.90M |
| March 31, 2022 | -1.014B |
| December 31, 2021 | -379.00M |
| September 30, 2021 | -616.50M |
| June 30, 2021 | -483.30M |
| March 31, 2021 | -1.284B |
| December 31, 2020 | -674.10M |
| September 30, 2020 | -313.50M |
| June 30, 2020 | -210.40M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.061B |
| December 31, 2019 | -41.40M |
| September 30, 2019 | -423.80M |
| June 30, 2019 | 61.00M |
| March 31, 2019 | -7.679B |
| December 31, 2018 | -659.00M |
| September 30, 2018 | -398.10M |
| June 30, 2018 | 3.133B |
| March 31, 2018 | -170.30M |
| December 31, 2017 | 1.653B |
| September 30, 2017 | -1.758B |
| June 30, 2017 | -2.249B |
| March 31, 2017 | -1.430B |
| December 31, 2016 | -1.178B |
| September 30, 2016 | -794.70M |
| June 30, 2016 | -1.021B |
| March 31, 2016 | -145.40M |
| December 31, 2015 | 253.70M |
| September 30, 2015 | -570.10M |
| June 30, 2015 | 182.40M |
| March 31, 2015 | 160.80M |
| December 31, 2014 | -2.179B |
| September 30, 2014 | -1.650B |
| June 30, 2014 | -468.90M |
| March 31, 2014 | 388.40M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -1.11B |
| Merck & Co., Inc. | -5.602B |
| Pfizer Inc. | 2.106B |
| Bristol Myers Squibb Co. | -1.614B |
| Atai Beckley, Inc. | 158.15M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 10.69B |
| Cash from Financing (Quarterly) | 8.426B |
| Free Cash Flow | 13.56B |
| Free Cash Flow Per Share (Quarterly) | 5.007 |
| Free Cash Flow to Equity (Quarterly) | -7.063B |
| Free Cash Flow to Firm (Quarterly) | 4.685B |
| Free Cash Flow Yield | 1.29% |